BackgroundThis antibody reacts with the human CD52 antigen, also known as CAMPATH-1. The CD52 antigen is a remarkably small peptide that is heavily glycosylated, and attached to the cell surface membrane via a GPI link. The apparent molecular mass of the antigen on SDS-PAGE is 25-29kD. CD52 is expressed at high density by lymphocytes, monocytes, eosinophils, thymocytes and macrophages. It is expressed by most lymphoid derived malignancies, although expression on myeloma cells is variable.Humanised versions of CAMPATH-1 specific antibodies are currently in clinical trials for the treatment of a range of lymphoid malignancies.

Product1 litre of aqua demin. (0.5-1 μSi / cm) + 10 PBS tablets + 5 g BSA + 0.9 g Na azide

Concentration: 1 mg/ml

Applications

Working Concentration: (liquid conc.)

Positive Control: Tonsil

Storage2-8°C

CautionThis product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Nordic-MUbio​ accepts no liability for any inaccuracies or omissions in this information.

References1. Hale, G. et al. (1998). Improving the Outcome of Bone Marow Transplantation by using CD52 Monoclonal Antibodies to prevent graft-versus-host disease and graft rejection. Blood 92: 4581-45902. Salisbury, J.R. et al. (1994). Immunohistochemical analysis of CDw52 antigen expression in non-hodgkins lymphomas. J. Clin. Path. 47: 313 - 317.